Single-Photon Emission Computed Tomography Market Analysis

Global Single-Photon Emission Computed Tomography Market Overview

Single-Photon Emission Computed Tomography Market Size was valued at USD 1.5 Billion in 2022. The single-photon emission computed tomography market industry is projected to grow from USD 1.60 Billion in 2023 to USD 2.73 Billion by 2032, displaying a compound annual growth rate (CAGR) between 2023 and 2032 of 6.90%. The rising prevalence of diseases brought on by stress, bad eating habits, and changing lifestyles are the key market drivers enhancing market growth. Further predicted to moderate the growth of the single photon emission computerized tomography (SPECT) market is the growing awareness of its application and the benefits associated with using preclinical imaging among physicians and patients.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

In June 2022, Siemens Healthineers launched Symbia Pro.specta, a SPECT/CT system that combines single photon emission computed tomography and computed tomography. This system has received the CE mark and clearance from the Food and Drug Administration (FDA), and it incorporates sophisticated imaging technologies for SPECT and CT. The system offers a low-dose CT with a maximum of 64 slices to provide highly detailed images.

October 2022: The Division of Artificial Intelligence in Medicine at Cedars-Sinai has created artificial intelligence (AI) models that enhance the quality and precision of heart imaging, forecast heart attacks and other significant adverse cardiac events, and diagnose coronary artery disease. Based on the study, attenuation correction is necessary for SPECT imaging in order to minimize artifacts in cardiac images.

Single-Photon Emission Computed Tomography Market Trends

• Rapid technological upgradation of C.T. Scan is driving the market growth

Market CAGR for single photon emission computerized tomography (SPECT) is driven by the rapid advancement of C.T. scanners. The development of technologically advanced single photon emission computerized tomography (SPECT) scanners is one of the main factors propelling market progress. The key industry participants are constantly working to create technologically advanced items. The length of hospital stays has been greatly decreased thanks to single photon emission computerized tomography (SPECT) scanners, which have also improved cancer diagnosis. Recent developments in single photon emission computerized tomography (SPECT) scanning technology include reduced patient radiation exposure, accelerated scanning times, and enhanced image quality. Technology-advanced products are being released on the market by leading manufacturers. After developing 64-slice CT systems, major market players created higher-slice CT systems to, among other things, improve image quality, speed up scanning, and get rid of stitching artifacts.

The growing demand for SPECT scanners—single photon emission computerized tomography—and developing healthcare systems in developing countries are the key drivers of this increase.  The need for advanced imaging technologies, particularly computed tomography, is expected to be considerably impacted by this and the rising prevalence of chronic diseases worldwide. For instance, the American Heart Association estimates that 121.5 million persons in the United States suffered cardiovascular ailments in 2018. The British Heart Foundation estimates that 7.6 million people in the U.K. will have cardiovascular disorders in 2021. A sizable patient pool for imaging operations is anticipated due to the rising number of patients with chronic illnesses. Thus, driving the single-photon emission computed tomography market revenue.

Single-Photon Emission Computed Tomography Market Segment Insights

Single-Photon Emission Computed Tomography Type Insights

The  single-photon emission computed tomography market segmentation, based on type, includes hybrid SPECT systems and standalone SPECT systems. The hybrid SPECT systems segment is anticipated to expand throughout the projection period. Healthcare professionals have been observed in recent years transitioning from solo to hybrid SPECT methods. Advanced hybrid SPECT systems provide greater clinical usefulness for imaging. Technology development and the discovery of new hybrid SPECT scanners contribute to the segment's expansion. Healthcare practitioners still frequently employ standalone SPECT systems. The oncology sector typically uses standalone SPECT systems. However, the quick uptake of hybrid SPECT systems in hospitals will probably affect how much the standalone SPECT systems market expands.

Single-Photon Emission Computed Tomography Application Insights

The  single-photon emission computed tomography market segmentation, based on application, includes oncology, cardiology, and neurology. The cardiology segment dominated the market, accounting for 46.6% of market revenue (0.7 Billion). The demand for SPECT scanners from cardiology departments worldwide has increased due to the number of patients with coronary artery disorders and other heart-related diseases. Cardiologists employ SPECT scanners to examine blood flow in the veins and pinpoint the precise nature of heart disease. Cardiovascular illness is diagnosed or identified by injecting a radioactive tracer labeled with gamma cameras. The oncology sector also influenced the market in 2022. The factors anticipated to propel the market include the rising incidence of cancer and the expanding use of SPECT scans in detecting various malignancies, including lumps and tumors.

Figure 1  Single-Photon Emission Computed Tomography Market, by Application, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Single-Photon Emission Computed Tomography End-User Insights

The  single-photon emission computed tomography market segmentation, based on end-user, includes hospitals and diagnostic imaging centers. Due to the rising spending on hospitals in the healthcare industry, the hospitalS segment has the greatest revenue share in the market. The rise in patients being admitted to hospitals is a major component in the hospital segment's expansion. Hospitals have a large SPECT scanner purchase capability. The rising use of cutting-edge imaging technologies in hospitals fuels the segment's rise. After hospitals, the specialty diagnostic center segment has the quickest growth rate. Due to increased investment in diagnostic centers, the diagnostic center segment is anticipated to expand favorably throughout the projection period.

Single-Photon Emission Computed Tomography Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American single-photon emission computed tomography market area will dominate this market. One of the main factors influencing the market's expansion is the healthcare industry's quick adoption of modern imaging technology in North America. The region's SPECT market is expanding due to more and more radiopharmaceutical devices for computed imaging being discovered. Demand for efficient molecular imaging SPECT scanners has increased recently due to an increase in cancer and cardiovascular disease cases.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2  SINGLE PHOTON EMISSION COMPUTERISED TOMOGRAPHY (SPECT)MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s single-photon emission computed tomography market accounts for the second-largest market share due to rising chronic disease awareness, well-established healthcare facilities in Germany, France, and Italy, and rising demand from these facilities for modern healthcare systems. Further, the German single-photon emission computed tomography market held the major market share, and the UK single-photon emission computed tomography market was the rapidly growing market in the European region.

The Asia-Pacific Single-Photon Emission Computed Tomography Market is expected to expand at a rapid rate from 2023 to 2032. Due to the region's rapidly expanding economies, particularly those of China and India, and the region's expanding healthcare infrastructure, the market for single photon emission computerized tomography (SPECT) is expected to grow at a strong CAGR in Asia Pacific throughout the forecast period. Additionally, expanding local producers and the rising frequency of chronic diseases are anticipated to support market expansion. Moreover, China’s single-photon emission computed tomography market held the largest market share, and the Indian single-photon emission computed tomography market was the rapidly growing market in the Asia-Pacific region.

Single-Photon Emission Computed Tomography Key Market Players & Competitive Insights

Leading market players are largely investing in research and development to expand their product lines, which will help the single photon emission computerized tomography (SPECT) grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their  presence. The single-photon emission computed tomography industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the  single-photon emission computed tomography industry to increase the market sector and benefits customers is local manufacturing to lower operational costs. In recent years, the single-photon emission computed tomography industry has stipulated some of the most important medicinal benefits.  Major players in the single-photon emission computed tomography industry, including Siemens Healthcare, Koninklijke Philips N.V., Mediso Ltd., Spectrum Dynamics Medical, GE Healthcare, and others, are funding operations for research and development to boost market demand.

Spectrum Dynamics creates nuclear imaging technologies for medical applications for patients and clinicians. Hand-held nuclear imaging instruments for cancer diagnosis, CZT detectors for SPECT imaging, and other nuclear medicine applications are available in the United States, Europe, Japan, and other markets. In October 2022, Spectrum Dynamics revealed its most recent advancement in digital nuclear medicine imaging the capacity to image high energy isotopes employing solid-state detector technology in a 3600 -CZT-based, wide-bore SPECT/CT configuration. This capability is included in the new VERITON-CT 400 Series Digital SPECT/CT scanners, allowing for total body, brain, heart, and other imaging applications.

Siemens Healthineers AG (Siemens Healthineers) is a medical technology firm that designs, develops, manufactures, and distributes diagnostic imaging systems, clinical and workflow systems and solutions, and systems for minimally invasive treatments. The company's main products include molecular imaging systems, X-ray products, computed tomography systems, magnetic resonance imaging systems, and testing systems. In June 2022, Siemens Healthineers received FDA approval for the Symbia Pro. It is a single-photon emission computed tomography/computed tomography (SPECT/CT) system combining advanced CT and SPECT imaging technologies. Among the capabilities are a low-dose CT with up to 64 slices for outstanding detail, automatic SPECT motion correction for further picture clarity, and a simple and automated workflow to guide the user through the full examination decision-making process. 

Key Companies in the single-photon emission computed tomography market include

• GE Healthcare


• Siemens Healthcare


• Mediso Ltd.


• Digirad Corporation


• Spectrum Dynamics Medical


• DDD-Diagnostic A/S


• Koninklijke Philips N.V.


• Bruker Corporation


• MiE America Inc.


• CardiArc

Single-Photon Emission Computed Tomography Industry Developments

March 2022 GE Healthcare wants to enhance its product portfolio with two pipeline radiopharmaceuticals, one for Positron Emission Tomography (PET) and the other for single-photon release calculated tomography imaging. According to a report from the business, the first patient in Phase III clinical trial for a PET radiopharmaceutical imaging intermediate that aims to assess adult patients with suspected Parkinsonian disorders, conduct research, and enhance patient maintenance has received medication.

March 2020 Curium announced that the Pulmotech MAA had been authorized by the US Food and Drug Administration (FDA). Pulmotech MAA is a single-photon emission agent for lung imaging when labeled to technetium Tc 99m as an auxiliary in evaluating pulmonary perfusion and, in adults, to aid in evaluating peritoneovenous shunt patency.

Single-Photon Emission Computed Tomography Market Segmentation

Single-Photon Emission Computed Tomography Type Outlook

• Hybrid SPECT Systems


• Standalone SPECT System

Single-Photon Emission Computed Tomography Application Outlook

• Oncology


• Cardiology


• Neurology

Single-Photon Emission Computed Tomography End-User Outlook

• Hospitals


• Diagnostic Imaging Centers

Single-Photon Emission Computed Tomography Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America